Phosphate-binding drug does not improve heart health of patients with mild kidney disease

The phosphate binder sevelamer carbonate did not improve cardiovascular measures in patients with early chronic kidney disease. For now, reducing dietary intake of phosphate may be the best way for these patients to reduce the mineral's negative effects on the heart. High phosphate levels -- in kidney disease patients and in the general population -- increase the risk of dying from cardiovascular causes.

Read the whole article on Eurekalert

More from Eurekalert